Michael Henderson, the CEO of Apogee Therapeutics Inc (APGE, Financial), sold 40,000 shares of the company on October 2, 2024. The transaction was disclosed in a recent SEC filing. Following this sale, the insider now owns 1,354,487 shares of the company.
Apogee Therapeutics Inc is engaged in the development and commercialization of various therapeutic treatments. The company focuses on innovative solutions to address unmet medical needs in the healthcare sector.
On the day of the sale, shares of Apogee Therapeutics Inc were priced at $56.23, valuing the company with a market cap of approximately $3.09 billion. This valuation reflects the company's standing and investor expectations within the pharmaceutical industry.
Over the past year, Michael Henderson has sold a total of 135,000 shares and has not made any purchases of the company's stock. The recent transaction is part of a series of sales by the insider, indicating a consistent pattern of stock divestiture.
The insider transaction history for Apogee Therapeutics Inc shows a trend of more insider sales than buys over the past year, with 9 insider sells and 0 insider buys. This could be indicative of the insiders' perspectives on the stock's valuation and future prospects.
For further insights into the company's valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors can visit the respective links.
This insider sell event is a significant transaction for Apogee Therapeutics Inc and its stakeholders, providing insights into insider actions and potential implications for the stock's future performance.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
